WASHINGTON Federal regulators have granted Anglo-Swedish drugmaker AstraZeneca approval to market its cholesterol pill Crestor as a preventive measure against heart attack and stroke in patients with healthy cholesterol levels.
Cornerstone Pharmaceuticals Inc., a privately held, clinical stage oncology-focused pharmaceutical company, has announced the closing of its Series B-4 private equity financing of $6,175,000.
02/09/10 Crucell Announces Record Revenues and Profits for Full Year 2009. Total revenues and other operating income increased 26% to EUR358.0 million. Operating profit increased more than four-fold to EUR39.0 million. Net profit increased 68% to EUR23.9 million. Undiluted EPS increased 55% to EUR0.34. Year-end cash and short-term liquidities EU
Elan Drug Technologies, a business unit of Elan Corporation, plc issued the following statement regarding the U.S. Food and Drug Administration approval of AMPYRA as a treatment to improve walking in patients with multiple sclerosis.
ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration has notified the company that the Oncologic Drugs Advisory Committee public advisory meeting scheduled for 10 February 2010 has been suspended due to extreme weather conditions in Washington D.C. The ODAC meeting was scheduled to review two New Drug Applica
Braintree,Ma. LevelStock.com is pleased to announce to all of its members and investors information on Cell Therapeutics, Inc. The Company released news as follows: Cell Therapeutics, Inc. announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is p
MedCI LLC, a life-science business consulting services company, announced the formation of a new strategic alliance with Genta Incorporated to secure licensing partners for Genta's small molecule oncology compound, tesetaxel.
Merge Healthcare has successfully deployed its etrials eDiary 5.0 platform to conduct a global Phase II urology clinical trial involving 750 patients for one of the largest pharmaceutical companies in the world.
Novella Clinical Inc. and OSI Pharmaceuticals, Inc. announced that the Companies will expand their existing clinical service agreement. "We are excited to be expanding our footprint and adding to our Novella family," stated W. Richard Staub, President and Chief Executive Officer of Novella Clinical.
OncoVista Innovative Therapies, Inc. announced that its wholly owned subsidiary, AdnaGen AG, the manufacturer of CE-certified circulating tumor cell diagnostic assays, has entered into an agreement with TATAA Molecular Diagnostics, for the exclusive use of its Adnatest BreastCancer assays in an international breast cancer research COHERTA project.
Addex Pharmaceuticals Inc., of Geneva, said ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. Affimed Therapeutics AG, of Heidelberg, Germany, said AFM 13 was well tolerated and showed evidence of preclinical efficacy for Hodgkin's lymphoma.
Patient Safety Technologies, Inc. announced the appointment of Eugene A. Bauer, MD and William M. Hitchcock to its Board of Directors. Dr. Bauer is President & Chief Medical Officer and immediate past member of the Board of Directors of Peplin, Inc., a dermatology company that was, until recently, traded on the ASX in Australia.
TopoTarget A/S Symbion Fruebjergvej 3 DK 2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92 CVR-nr: 25695771 www.topotarget.com Copenhagen, Denmark - 3 December 2009 - TopoTarget A/S expects to publish financial reports on the following dates next year: Annual report for 2009 25 March 2010 Financial report for the first quarter of 2
DALLAS, TEXAS : StockGuru announces that Transgenomic Inc. is in the StockGuru Spotlight. On Monday, the company put out news announcing that it has completed a preliminary study with a leading pharmaceutical company that validates the use of its licensed COLD-PCR technology to detect colorectal tumor-associated KRAS mutations that determine effica
WILMINGTON, Del., Feb. 8AstraZeneca today announced that the US Food and Drug Administration has approved CRESTOR to reduce the risk of stroke, myocardial infarction and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age, high-sen
SHENYANG, China, Feb. 83SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil pharmaceutical product for the treatment of hyperphosp
Afferent Pharmaceuticals, a pharmaceutical company focused on developing first-in-class medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers, announced the appointment of Bruce G. McCarthy, M.D., as chief executive officer.
- New "Soutschek and Manoharan" Patent Covers Chemically Modified Small Interfering RNAs with Drug-Like Properties for In Vivo Delivery - Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has awarded a Notice of Allowance for the "Soutschek and Manoharan" patent, w
Today, the Academy of Managed Care Pharmacy and Dymaxium Healthcare Innovations, Ltd. launch the AMCP eDossier System Pilot Program. The AMCP eDossier System combines the familiar structure of paper-based dossiers with technologies that are flexible and interactive, while maintaining strict adherence to regulatory standards.
Achieve "Meaningful Use" of EHR Regardless of the Technology. AmerisourceBergen announced a unique offering designed to help hospitals and health systems achieve meaningful use readiness for electronic health records, regardless of the technology they are using.
Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength in tablet form effective December 9, 2009. Tramadol/APAP is a centrally-acting analgesic indicated for the short-term management of moderately severe acute pain.
HAYWARD, Calif., Feb. 8Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the Phase 3 clinical study named VISTA-16 for its lead
